Ladenburg Thalmann Financial Services Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 34,060 shares of the company’s stock after selling 1,309 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $1,827,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Aevitas Wealth Management Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $107,000. Zions Bancorporation raised its stake in shares of Novo Nordisk A/S by 677.1% during the third quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock valued at $137,000 after purchasing an additional 2,485 shares in the last quarter. SeaCrest Wealth Management LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $176,000. Addenda Capital Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $201,000. Finally, Charter Trust Co. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $201,000. 6.71% of the stock is owned by institutional investors.
Shares of Novo Nordisk A/S (NYSE NVO) opened at $48.49 on Monday. Novo Nordisk A/S has a one year low of $33.42 and a one year high of $58.37. The firm has a market cap of $118,486.68, a PE ratio of 20.90, a P/E/G ratio of 2.37 and a beta of 0.60.
Novo Nordisk A/S announced that its Board of Directors has approved a stock repurchase program on Thursday, February 1st that allows the company to repurchase outstanding shares. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
The firm also recently declared a special dividend, which will be paid on Tuesday, April 3rd. Shareholders of record on Monday, March 26th will be given a $0.8117 dividend. This represents a yield of 0.96%. The ex-dividend date is Friday, March 23rd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 35.34%.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research note on Tuesday, January 2nd. Bank of America upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. JPMorgan Chase & Co. upgraded shares of Novo Nordisk A/S from an “underweight” rating to a “neutral” rating in a research note on Friday, December 29th. Deutsche Bank restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, January 8th. Finally, Morgan Stanley upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.